ABTECT maintenance
75 evidence topics · 13 sources
Objective
Objective of the subgroup presentation by prior advanced therapy response
Purpose and primary objectives of Part 1 and Part 2 in the ClinicalTrials.gov record
Main objectives of Part 1, Part 2, and the long-term extension in the EU register
Location and study date
Study dates and number of locations in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-16” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-04-28” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2030-05” (opens the source at this quote in a new tab)
“This study has 413 locations” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Countries, sites, and trial duration in the EU register
Phase 3 program: 36 countries and over 600 sites, first U.S. participant in October 2022
Part 2 topline results announced June 29, 2026
Presentation at UEG Week 2026 in Barcelona
Study design
Official title and design details in the ClinicalTrials.gov record
Two treatment phases: a 44-week maintenance phase (Part 1 and Part 2) and a 4-year long-term extension
Randomization by induction treatment and response status
Part 1: re-randomization of obefazimod induction responders to 25 mg, 50 mg, or placebo
Responder definition, stratification factors, and placebo induction responders
Part 2: induction non-responders and Part 1 relapsers
Central endoscopy reading and primary endpoint at the end of the 44-week maintenance trial (52 weeks in total)
Eligibility criteria
Inclusion criteria for the maintenance phase in the ClinicalTrials.gov record
Exclusion criteria for the maintenance phase in the ClinicalTrials.gov record
Minimum age of 16 years, or 18 years in the EU/EEA, Israel, Serbia, and Ukraine
Long-term extension entry criteria
Treatment
Long-term extension: continued allocated treatment for up to 4 years
Investigational products: 25 mg and 50 mg hard capsules and matching placebo
Dose escalation to open-label 50 mg after relapse in Part 1
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
FDA recommendation: proportion in clinical remission by the modified Mayo Score as the primary endpoint
FDA recommendation: induction followed by randomized withdrawal maintenance with evaluation at about 52 weeks
FDA recommendation: remission in participants entering maintenance in remission to show durability
Company definition of the primary endpoint and its basis in FDA guidance
Primary endpoint and key secondary endpoints as presented at UEG Week 2026
Corticosteroid-free clinical remission: registered in the subpopulation receiving corticosteroids at maintenance entry
EU register: endoscopic improvement and symptomatic remission as Part 1 primary endpoints, clinical remission as a secondary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned participants in the EU register
Induction responders entering Part 1: 678 of 1,275
Part 1 analysis population: 580 obefazimod induction responders
| Group | Participants |
|---|---|
| Obefazimod induction responders | “Obefazimod Induction Responders (n=580)” |
| Placebo | “Placebo (n=192)” |
| Obefazimod 25 mg | “25 mg (n=193)” |
| Obefazimod 50 mg | “50 mg (n=195)” |
Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy
Part 2 safety population: 186 participants on 25 mg and 447 on 50 mg
Description of analysis sets
Treatment differences: Mantel-Haenszel common risk difference adjusted for the stratification factors
Multiplicity control of the key secondary endpoints
Subgroup analyses by prior advanced therapy response: unadjusted differences and nominal p-values
Part 2 and integrated safety analyses: post-hoc, exposure-adjusted
Results
Participant disposition
Week 44 completion without relapse or treatment switch, by group
| Measure | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
|---|---|---|---|
| Study participants | “192” | “193” | “195” |
| Week 44 completion rate | “66 (34.3%)” | “152 (78.8%)” | “160 (82.1%)” |
Completion of the 44-week maintenance phase at the December 2025 data safety monitoring board review
Completion of the 44-week treatment period at the March 2026 data safety monitoring board review
Baseline characteristics
Part 1 baseline characteristics by group
| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
|---|---|---|---|
| Study participants | “192” | “193” | “195” |
| Age (years), mean (SD) | “41.3 (13.4)” | “43.0 (13.7)” | “42.3 (14.4)” |
| Induction baseline modified Mayo Score, mean (SD) | “6.9 (1.1)” | “6.7 (1.1)” | “6.9 (1.2)” |
| Duration of disease (years), mean (SD) | “8.1 (7.6)” | “8.1 (7.4)” | “7.8 (6.9)” |
| Induction baseline fecal calprotectin (mg/g), median | “1,202” | “1,585” | “1,568” |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |
| Clinical remission at maintenance baseline | “27.1%” | “37.8%” | “32.3%” |
| Prior advanced therapy failure | “37.5%” | “39.4%” | “46.2%” |
Higher proportion with prior advanced therapy failure in the 50 mg group
Definition of prior inadequate response to advanced therapy
Efficacy results
Part 1 primary and key secondary endpoints at Week 44
| Endpoint at Week 44 | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) | Difference, 25 mg | Difference, 50 mg | P value (both doses) |
|---|---|---|---|---|---|---|
| Clinical remission, n (%) | “20 (10.4%)” | “98 (50.8%)” | “100 (51.3%)” | “∆39.3%” | “∆40.3%” | “<0.0001” |
| Endoscopic improvement, n (%) | “24 (12.5%)” | “106 (54.9%)” | “125 (64.1%)” | “∆42.5%” | “∆51.0%” | “<0.0001” |
| Endoscopic remission, n (%) | “19 (9.9%)” | “80 (41.5%)” | “93 (47.7%)” | “∆31.4%” | “∆37.8%” | “<0.0001” |
| HEMI, n (%) | “20 (10.4%)” | “97 (50.3%)” | “112 (57.4%)” | “∆39.4%” | “∆46.5%” | “<0.0001” |
| Corticosteroid-free clinical remission, n (%) | “19 (9.9%)” | “87 (45.1%)” | “93 (47.7%)” | “∆35.1%” | “∆38.0%” | “<0.0001” |
| Sustained clinical remission, n/N (%) | “8/51 (15.7%)” | “49/73 (67.1%)” | “40/61 (65.6%)” | “∆52.8%” | “∆49.1%” | “<0.0001” |
Placebo clinical remission rate of 10.4% as characterized by the company
Week 52 reporting at UEG Week 2026: the same results expressed as 52 weeks of treatment overall
Other secondary endpoints at Week 52: clinical response and symptomatic remission
| Endpoint at Week 52 | Placebo, n/N | Placebo, % | Obefazimod 25 mg, n/N | Obefazimod 25 mg, % | Obefazimod 50 mg, n/N | Obefazimod 50 mg, % | Difference, 25 mg | Difference, 50 mg |
|---|---|---|---|---|---|---|---|---|
| Clinical response | “51/192” | “26.6%” | “135/193” | “69.9%” | “147/195” | “75.4%” | “∆ 42.8%” | “∆ 49.7%” |
| Symptomatic remission | “44/192” | “22.9%” | “129/193” | “66.8%” | “128/195” | “65.6%” | “∆ 42.5%” | “∆ 41.0%” |
Clinical endpoints at Week 52 by prior inadequate response to advanced therapy
| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
|---|---|---|---|---|---|---|---|
| No prior AT-IR: clinical remission | “15/120” | “72/117” | “62/105” | “∆ 48%” | “p<0.0001” | “∆ 45%” | “p<0.0001” |
| No prior AT-IR: corticosteroid-free clinical remission | “15/120” | “64/117” | “59/105” | “∆ 42%” | “p<0.0001” | “∆ 43%” | “p<0.0001” |
| No prior AT-IR: sustained clinical remission | “5/38” | “42/58” | “27/38” | “∆ 62%” | “p<0.0001” | “∆ 55%” | “p=0.0003” |
| Prior AT-IR: clinical remission | “5/72” | “26/76” | “38/90” | “∆ 28%” | “p<0.0001” | “∆ 33%” | “p<0.0001” |
| Prior AT-IR: corticosteroid-free clinical remission | “4/72” | “23/76” | “34/90” | “∆ 26%” | “p=0.0001” | “∆ 31%” | “p<0.0001” |
| Prior AT-IR: sustained clinical remission | “3/13” | “7/15” | “13/23” | “∆ 24%” | “p=0.6873” | “∆ 30%” | “p=0.0915” |
Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy
| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N |
|---|---|---|---|
| No prior AT-IR: endoscopic improvement | “18/120” | “77/117” | “77/105” |
| No prior AT-IR: endoscopic remission | “15/120” | “62/117” | “58/105” |
| No prior AT-IR: HEMI | “15/120” | “71/117” | “68/105” |
| Prior AT-IR: endoscopic improvement | “6/72” | “29/76” | “48/90” |
| Prior AT-IR: endoscopic remission | “4/72” | “18/76” | “35/90” |
| Prior AT-IR: HEMI | “5/72” | “26/76” | “44/90” |
Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure
| Subgroup | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
|---|---|---|---|---|---|---|---|
| No prior AT-IR | “15/120” | “72/117” | “62/105” | “∆ 49%” | “p<0.0001” | “∆ 47%” | “p<0.0001” |
| One prior AT-IR | “4/27” | “12/31” | “17/41” | “∆ 24%” | “p=0.2785” | “∆ 27%” | “p=0.0584” |
| Two prior AT-IR | “0/24” | “7/22” | “8/19” | “∆ 32%” | “p=0.0215” | “∆ 42%” | “p=0.0014” |
| Three prior AT-IR | “1/12” | “4/12” | “10/21” | “∆ 25%” | “p=0.0771” | “∆ 39%” | “p=0.0968” |
| Four or more prior AT-IR | “0/9” | “3/11” | “3/9” | “∆ 27%” | “NC” | “∆ 33%” | “p=0.1967” |
| Prior JAK inhibitor inadequate response | “0/16” | “4/14” | “5/15” | “∆ 29%” | “p=0.0190” | “∆ 33%” | “p=0.0375” |
Conclusions of the subgroup presentation
Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44
Health-related quality of life and patient-reported outcomes
IBDQ response: long-term extension endpoint in the EU register, no results reported
Safety results
Part 1 treatment-emergent adverse events over 44 weeks
| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
|---|---|---|---|
| Any TEAE | “96 (50.0%)” | “112 (58.0%)” | “140 (71.8%)” |
| TEAE leading to study drug discontinuation | “13 (6.8%)” | “5 (2.6%)” | “9 (4.6%)” |
| Serious TEAE | “8 (4.2%)” | “5 (2.6%)” | “11 (5.6%)” |
| Death | “0” | “0” | “0” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “2 (1.0%)” | “2 (1.0%)” | “1 (0.5%)” |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |
| Malignancy other than NMSC: prostate cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: breast cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: colonic dysplasia | “0” | “0” | “1 (0.5%)” |
| NMSC: basal cell carcinoma | “1 (0.5%)” | “0” | “2 (1.1%)” |
| NMSC: squamous cell carcinoma | “0” | “1 (0.5%)” | “2 (1.1%)” |
Part 1 malignancies and non-melanoma skin cancers as described by the company
Part 1 related serious adverse events, pregnancies, and colonic dysplasia as presented at UEG Week 2026
| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
|---|---|---|---|
| Patients with any related serious TEAE | “1 (0.5%)” | “0” | “0” |
| Pregnancy | “0” | “0” | “2 (1.1%)” |
Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers
| Event, n (%) | Obefazimod 25 mg (N=186) | Obefazimod 50 mg (N=447) |
|---|---|---|
| Any TEAE | “132 (71.0%)” | “307 (68.7%)” |
| TEAE leading to study drug discontinuation | “21 (11.3%)” | “27 (6.0%)” |
| Serious TEAE | “16 (8.6%)” | “23 (5.1%)” |
| Death, not treatment related | “1 (0.5%)” | “0” |
| Pregnancy | “1 (0.5%)” | “1 (0.2%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “5 (2.7%)” | “5 (1.1%)” |
| Malignancies excluding NMSC | “0” | “2 (0.4%)” |
| NMSC | “2 (1.1%)” | “2 (0.4%)” |
| Acute pancreatitis | “1 (0.5%)” | “1 (0.2%)” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” |
Part 2 death, infections, and malignancies: footnotes to the safety table
Part 2 malignancies and non-melanoma skin cancers: case characteristics and investigator assessment
| Case | Dose | Exposure to obefazimod | Age | Thiopurine history | Medical history of cancer or skin cancer | Investigator assessment |
|---|---|---|---|---|---|---|
| Myeloproliferative neoplasm | “50 mg” | “7.4 months” | “40+” | “No” | “No” | “Determined not related to study drug by investigator” |
| Prostate cancer | “50 mg” | “3.4 months” | “55+” | “Yes azathioprine” | “No” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “50 mg” | “10.4 months” | “40+” | “Yes azathioprine” | “No” | “Determined probably related to study drug by investigator” |
| Squamous cell carcinoma | “50 mg” | “4.6 months” | “55+” | “Yes azathioprine” | “Yes” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “25 mg” | “8.1 months” | “50+” | “Yes azathioprine” | “No” | “Determined unlikely related to study drug by investigator” |
| Squamous cell carcinoma | “25 mg” | “8.3 months” | “75+” | “No” | “Yes” | “Determined probably related to study drug by investigator” |
Part 2 malignancies and non-melanoma skin cancers as described by the company
Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range
| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
|---|---|---|---|---|---|
| Integrated UC program (phase 2 and phase 3) | “0.00” | “0.00” | “0.64” | “0.35” | “0.30 – 0.70” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.00” | “0.00” | “0.91” | “0.56” | “0.30 – 0.70” |
| Part 2 only | “-” | “0.00” | “0.69” | “0.48” | “0.30 – 0.70” |
Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range
| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
|---|---|---|---|---|---|
| Integrated UC program (phase 2 and phase 3) | “0.46” | “0.53” | “0.64” | “0.59” | “0.70 – 1.40” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.68” | “1.09” | “1.37” | “1.26” | “0.70 – 1.40” |
| Part 2 only | “-” | “1.52” | “0.69” | “0.95” | “0.70 – 1.40” |
Company interpretation of the exposure-adjusted malignancy analyses
Interim data safety monitoring board reviews in December 2025 and March 2026
Study limitations
Summary
As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.
Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.
The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.
Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.
Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.
Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.